Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 937398, 21 pages
http://dx.doi.org/10.1155/2014/937398
Review Article

Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review

Nephrology Department, Faculty of Medicine, University of Medicine and Pharmacy “Gr. T. Popa”, Strada. Universităţii No. 16, 700115 Iaşi, Romania

Received 5 February 2014; Revised 21 April 2014; Accepted 22 April 2014; Published 15 May 2014

Academic Editor: Mitja Lainscak

Copyright © 2014 Liviu Segall et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U.S. Renal Data System (USRDS), “Chronic kidney disease in the adult NHANES population,” USRDS Annual Report Data, 2009, http://www.usrds.org/2009/pdf/V1_01_09.PDF. View at Google Scholar
  2. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Clinical epidemiology of cardiovascular disease in chronic renal disease,” The American Journal of Kidney Diseases, vol. 32, no. 5, supplement 3, pp. S112–S119, 1998. View at Google Scholar · View at Scopus
  3. D. W. Johnson, A. Craven, and N. M. Isbel, “Modification of cardiovascular risk in hemodialysis patients: an evidence-based review,” Hemodialysis International, vol. 11, no. 1, pp. 1–14, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. S. M. Bagshaw, D. N. Cruz, N. Aspromonte et al., “Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI consensus conference,” Nephrology Dialysis Transplantation, vol. 25, no. 5, pp. 1406–1416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Kottgen, S. D. Russell, L. R. Loehr et al., “Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study,” Journal of the American Society of Nephrology, vol. 18, no. 4, pp. 1307–1315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Soucie and W. M. McClellan, “Early death in dialysis patients: risk factors and impact on incidence and mortality rates,” Journal of the American Society of Nephrology, vol. 7, no. 10, pp. 2169–2175, 1996. View at Google Scholar
  7. J. D. Harnett, R. N. Foley, G. M. Kent, P. E. Barre, D. Murray, and P. S. Parfrey, “Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors,” Kidney International, vol. 47, no. 3, pp. 884–890, 1995. View at Google Scholar · View at Scopus
  8. A. Y. Wang, M. Wang, C. W. Lam, I. H. Chan, S. Lui, and J. E. Sanderson, “Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 4, pp. 805–812, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. F. C. Trespalacios, A. J. Taylor, L. Y. Agodoa, G. L. Bakris, and K. C. Abbott, “Heart failure as a cause for hospitalization in chronic dialysis patients,” The American Journal of Kidney Diseases, vol. 41, no. 6, pp. 1267–1277, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. R. N. Foley, P. S. Parfrey, J. D. Harnett et al., “Clinical and echocardiographic disease in patients starting end-stage renal disease therapy,” Kidney International, vol. 47, no. 1, pp. 186–192, 1995. View at Google Scholar · View at Scopus
  11. R. J. Glassock, R. Pecoits-Filho, and S. H. Barberato, “Left ventricular mass in chronic kidney disease and ESRD,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 1, pp. S79–S91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. A. Herzog, R. W. Asinger, A. K. Berger et al., “Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO),” Kidney International, vol. 80, no. 6, pp. 572–586, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Cerasola, E. Nardi, A. Palermo, G. Mulè, and S. Cottone, “Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review,” Journal of Nephrology, vol. 24, no. 1, pp. 1–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Zoccali, F. A. Benedetto, G. Tripepi, and F. Mallamaci, “Cardiac consequences of hypertension in hemodialysis patients,” Seminars in Dialysis, vol. 17, no. 4, pp. 299–303, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. B. López, A. González, N. Hermida, C. Laviades, and J. Díez, “Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide,” Kidney International, vol. 74, no. 111, pp. S19–S23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Amann, M. Breitbach, E. Ritz, and G. Mall, “Myocyte/capillary mismatch in the heart of uremic patients,” Journal of the American Society of Nephrology, vol. 9, no. 6, pp. 1018–1022, 1998. View at Google Scholar · View at Scopus
  17. E. Ritz, “Left ventricular hypertrophy in renal disease: beyond preload and afterload,” Kidney International, vol. 75, no. 8, pp. 771–773, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Gross and E. Ritz, “Hypertrophy and fibrosis in the cardiomyopathy of uremia—beyond coronary heart disease,” Seminars in Dialysis, vol. 21, no. 4, pp. 308–318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Ritz and C. Wanner, “The challenge of sudden death in dialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 3, pp. 920–929, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. R. J. Middleton, P. S. Parfrey, and R. N. Foley, “Left ventricular hypertrophy in the renal patient,” Journal of the American Society of Nephrology, vol. 12, no. 5, pp. 1079–1084, 2001. View at Google Scholar · View at Scopus
  21. E. Nardi, A. Palermo, G. Mulè, P. Cusimano, S. Cottone, and G. Cerasola, “Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease,” Journal of Hypertension, vol. 27, no. 3, pp. 633–641, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. S. J. Marchais, F. Metivier, A. P. Guerin, and G. M. London, “Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease,” Nephrology Dialysis Transplantation, vol. 14, no. 9, pp. 2178–2183, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Strózecki, A. Adamowicz, E. Nartowicz, G. Odrow̧z-Sypniewska, Z. Włodarczyk, and J. Manitius, “Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients,” Renal Failure, vol. 23, no. 1, pp. 115–126, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. C. D. Chue, N. C. Edwards, W. E. Moody, R. P. Steeds, J. N. Townend, and C. J. Ferro, “Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study,” Heart, vol. 98, no. 3, pp. 219–224, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Galetta, A. Cupisti, F. Franzoni et al., “Left ventricular function and calcium phosphate plasma levels in uraemic patients,” Journal of Internal Medicine, vol. 258, no. 4, pp. 378–384, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. V. Raizada, D. Hillerson, J. S. Amaram, and B. Skipper, “Angiotensin II-mediated left ventricular abnormalities in chronic kidney disease,” Journal of Investigative Medicine, vol. 60, no. 5, pp. 785–791, 2012. View at Google Scholar
  27. S. Steigerwalt, A. Zafar, N. Mesiha, J. Gardin, and R. Provenzano, “Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis,” The American Journal of Nephrology, vol. 27, no. 2, pp. 159–163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Grassi, G. Seravalle, L. Ghiadoni et al., “Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 11, pp. 2620–2627, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. National Institute of Clinical Excellence Chronic Heart Failure (NICE), National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care, Royal College of Physicians, London, UK, 2003, http://guidance.nice.org.uk/CG5.
  30. K. Dickstein, A. Cohen-Solal, G. Filippatos et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008,” European Heart Journal, vol. 29, no. 19, pp. 2388–2442, 2008. View at Publisher · View at Google Scholar
  31. A. Y. Wang and J. E. Sanderson, “Current perspectives on diagnosis of heart failure in long-term dialysis patients,” The American Journal of Kidney Diseases, vol. 57, no. 2, pp. 308–319, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. A. Hunt, W. T. Abraham, M. H. Chin et al., “2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the Aamerican College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation,” Circulation, vol. 119, no. 14, pp. e391–e479, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. R. S. Vasan, M. G. Larson, E. J. Benjamin, J. C. Evans, C. K. Reiss, and D. Levy, “Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort,” Journal of the American College of Cardiology, vol. 33, no. 7, pp. 1948–1955, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. T. J. Wang, J. C. Evans, E. J. Benjamin, D. Levy, E. C. LeRoy, and R. S. Vasan, “Natural history of asymptomatic left ventricular systolic dysfunction in the community,” Circulation, vol. 108, no. 8, pp. 977–982, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. W. J. Paulus, C. Tschöpe, J. E. Sanderson et al., “How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology,” European Heart Journal, vol. 28, no. 20, pp. 2539–2550, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Pecoits-Filho and S. H. Barberato, “Echocardiography in chronic kidney disease: diagnostic and prognostic implications,” Nephron—Clinical Practice, vol. 114, no. 4, pp. c242–c247, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. National Kidney Foundation, “K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients,” The American Journal of Kidney Diseases, vol. 45, no. 4, supplement 3, pp. S1–S153, 2005. View at Google Scholar
  38. C. Zoccali, F. A. Benedetto, F. Mallamaci et al., “Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression,” Kidney International, vol. 65, no. 4, pp. 1492–1498, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. R. N. Foley, P. S. Parfrey, G. M. Kent, J. D. Harnett, D. C. Murray, and P. E. Barre, “Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease,” Journal of the American Society of Nephrology, vol. 11, no. 5, pp. 912–916, 2000. View at Google Scholar · View at Scopus
  40. D. Bello, D. J. Shah, G. M. Farah et al., “Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing β-blocker therapy,” Circulation, vol. 108, no. 16, pp. 1945–1953, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. V. Wizemann and M. Schilling, “Dilemma of assessing volume state—the use and the limitations of a clinical score,” Nephrology Dialysis Transplantation, vol. 10, no. 11, pp. 2114–2117, 1995. View at Google Scholar · View at Scopus
  42. B. Charra, “Fluid balance, dry weight, and blood pressure in dialysis,” Hemodialysis International, vol. 11, no. 1, pp. 21–31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. K. S. Katzarski, J. Nisell, I. Randmaa, A. Danielsson, U. Freyschuss, and J. Bergstrom, “A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients,” The American Journal of Kidney Diseases, vol. 30, no. 4, pp. 459–465, 1997. View at Publisher · View at Google Scholar
  44. S. T. Chang, C. L. Chen, C. C. Chen, F. C. Lin, and D. Wu, “Enhancement of quality of life with adjustment of dry weight by echocardiographic measurement of inferior vena cava diameter in patients undergoing chronic hemodialysis,” Nephron—Clinical Practice, vol. 97, no. 3, pp. c90–c97, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Santoro, E. Mancini, C. Basile et al., “Blood volume controlled hemodialysis in hypotension-prone patients: a randomized, multicenter controlled trial,” Kidney International, vol. 62, no. 3, pp. 1034–1045, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. A. D. Sinha, R. P. Light, and R. Agarwal, “Relative plasma volume monitoring during hemodialysis aids the assessment of dry weight,” Hypertension, vol. 55, no. 2, pp. 305–311, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. J. J. Dasselaar, R. M. Huisman, P. E. de Jong, and C. F. M. Franssen, “Measurement of relative blood volume changes during haemodialysis: merits and limitations,” Nephrology Dialysis Transplantation, vol. 20, no. 10, pp. 2043–2049, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Agarwal, K. Kelley, and R. P. Light, “Diagnostic utility of blood volume monitoring in hemodialysis patients,” The American Journal of Kidney Diseases, vol. 51, no. 2, pp. 242–254, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Wabel, P. Chamney, U. Moissl, and T. Jirka, “Importance of whole-body bioimpedance spectroscopy for the management of fluid balance,” Blood Purification, vol. 27, no. 1, pp. 75–80, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Wizemann, P. Wabel, P. Chamney et al., “The mortality risk of overhydration in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 24, no. 5, pp. 1574–1579, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. P. MacHek, T. Jirka, U. Moissl, P. Chamney, and P. Wabel, “Guided optimization of fluid status in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 25, no. 2, pp. 538–544, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Mallamaci, F. A. Benedetto, R. Tripepi et al., “Detection of pulmonary congestion by chest ultrasound in dialysis patients,” JACC: Cardiovascular Imaging, vol. 3, no. 6, pp. 586–594, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Yasue, M. Yoshimura, H. Sumida et al., “Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure,” Circulation, vol. 90, no. 1, pp. 195–203, 1994. View at Google Scholar · View at Scopus
  54. K. Hosoda, K. Nakao, M. Mukoyama et al., “Expression of brain natriuretic peptide gene in human heart: production in the ventricle,” Hypertension, vol. 17, no. 6, part 2, pp. 1152–1155, 1991. View at Google Scholar · View at Scopus
  55. K. Yamamoto, J. C. Burnett Jr., M. Jougasaki et al., “Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy,” Hypertension, vol. 28, no. 6, pp. 988–994, 1996. View at Publisher · View at Google Scholar
  56. A. S. Maisel, P. Krishnaswamy, R. M. Nowak et al., “Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure,” The New England Journal of Medicine, vol. 347, no. 3, pp. 161–167, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. P. J. Hunt, A. M. Richards, M. G. Nicholls, T. G. Yandle, R. N. Doughty, and E. A. Espiner, “Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment,” Clinical Endocrinology, vol. 47, no. 3, pp. 287–296, 1997. View at Google Scholar
  58. J. Mant, J. Doust, A. Roalfe et al., “Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care,” Health Technology Assessment, vol. 13, no. 32, pp. 1–207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. J. C. Kelder, M. R. Cowie, T. A. McDonagh et al., “Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis,” Heart, vol. 97, no. 12, pp. 959–963, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Balion, P. L. Santaguida, S. Hill et al., “Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure,” Evidence Report/Technology Assessment, no. 142, pp. 1–147, 2006. View at Google Scholar · View at Scopus
  61. J. L. Januzzi Jr., “The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use,” Archives of Cardiovascular Diseases, vol. 105, no. 1, pp. 40–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Codognotto, A. Piccoli, M. Zaninotto et al., “Renal dysfunction is a confounder for plasma natriuretic peptides in detecting heart dysfunction in uremic and idiopathic dilated cardiomyopathies,” Clinical Chemistry, vol. 53, no. 12, pp. 2097–2104, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Takami, T. Horio, Y. Iwashima et al., “Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF,” The American Journal of Kidney Diseases, vol. 44, no. 3, pp. 420–428, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. F. S. Apple, M. A. M. Murakami, L. A. Pearce, and C. A. Herzog, “Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death,” Clinical Chemistry, vol. 50, no. 12, pp. 2279–2285, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Y. Wang, C. W. Lam, C. Yu et al., “N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients,” Journal of the American Society of Nephrology, vol. 18, no. 1, pp. 321–330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Mallamaci, C. Zoccali, G. Tripepi et al., “Diagnostic potential of cardiac natriuretic peptides in dialysis patients,” Kidney International, vol. 59, no. 4, pp. 1559–1566, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. G. Tripepi, F. Mattace-Raso, F. Mallamaci et al., “Biomarkers of left atrial volume: a longitudinal study in patients with end stage renal disease,” Hypertension, vol. 54, no. 4, pp. 818–824, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Y. Wang, “Clinical utility of natriuretic peptides in dialysis patients,” Seminars in Dialysis, vol. 25, no. 3, pp. 326–333, 2012. View at Google Scholar
  69. A. Y. Wang and J. E. Sanderson, “Treatment of heart failure in long-term dialysis patients: a reappraisal,” The American Journal of Kidney Diseases, vol. 57, no. 5, pp. 760–772, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. E. Ritz, R. Dikow, M. Adamzcak, and M. Zeier, “Congestive heart failure due to systolic dysfunction: the cinderella of cardiovascular management in dialysis patients,” Seminars in Dialysis, vol. 15, no. 3, pp. 135–140, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Özkahya, E. Ok, M. Cirit et al., “Regression of left ventricular hypertrophy in haemodialysis patient by ultrafiltration and reduced salt intake without antihypertensive drugs,” Nephrology Dialysis Transplantation, vol. 13, no. 6, pp. 1489–1493, 1998. View at Publisher · View at Google Scholar · View at Scopus
  72. A. I. Gunal, I. Karaca, B. Aygen, M. Yavuzkir, A. Dogukan, and H. Celiker, “Strict fluid volume control and left ventricular hypertrophy in hypertensive patients on chronic haemodialysis: a cross-sectional study,” Journal of International Medical Research, vol. 32, no. 1, pp. 70–77, 2004. View at Google Scholar · View at Scopus
  73. F. Aslam, A. Haque, J. Haque, and J. Joseph, “Heart failure in subjects with chronic kidney disease: best management practices,” World Journal of Cardiology, vol. 2, no. 5, pp. 112–117, 2010. View at Publisher · View at Google Scholar
  74. A. S. Abdo, A. Basu, and S. A. Geraci, “Managing chronic heart failure patient in chronic kidney disease,” The American Journal of Medicine, vol. 124, no. 1, pp. 26–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. D. M. Mancini, S. D. Katz, C. C. Lang, J. LaManca, A. Hudaihed, and A. Androne, “Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure,” Circulation, vol. 107, no. 2, pp. 294–299, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. D. S. Silverberg, D. Wexler, D. Sheps et al., “The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study,” Journal of the American College of Cardiology, vol. 37, no. 7, pp. 1775–1780, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. D. S. Silverberg, D. Wexler, M. Blum et al., “The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations,” Journal of the American College of Cardiology, vol. 35, no. 7, pp. 1737–1744, 2000. View at Publisher · View at Google Scholar · View at Scopus
  78. P. van der Meer, H. F. Groenveld, J. L. Januzzi Jr., and D. J. van Veldhuisen, “Erythropoietin treatment in patients with chronic heart failure: a meta-analysis,” Heart, vol. 95, no. 16, pp. 1309–1314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Levin, C. R. Thompson, J. Ethier et al., “Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin,” The American Journal of Kidney Diseases, vol. 34, no. 1, pp. 125–134, 1999. View at Google Scholar · View at Scopus
  80. A. Martinez-Vea, L. Marcas, A. Bardají et al., “Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease,” Clinical Nephrology, vol. 77, no. 3, pp. 171–181, 2012. View at Google Scholar · View at Scopus
  81. H. Schmid, H. Schiffl, and S. R. Lederer, “Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient,” Current Opinion in Nephrology and Hypertension, vol. 20, no. 5, pp. 465–470, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. R. N. Foley, P. S. Parfrey, J. Morgan et al., “Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy,” Kidney International, vol. 58, no. 3, pp. 1325–1335, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Besarab, W. K. Bolton, J. K. Browne et al., “The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin,” The New England Journal of Medicine, vol. 339, no. 9, pp. 584–590, 1998. View at Publisher · View at Google Scholar · View at Scopus
  84. T. B. Drüeke, F. Locatelli, N. Clyne et al., “Normalization of hemoglobin level in patients with chronic kidney disease and anemia,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2071–2084, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. A. K. Singh, L. Szczech, K. L. Tang et al., “Correction of anemia with epoetin alfa in chronic kidney disease,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2085–2098, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. M. A. Pfeffer, E. A. Burdmann, C. Chen et al., “A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease,” The New England Journal of Medicine, vol. 361, no. 21, pp. 2019–2032, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. S. A. J. Timmer, K. de Boer, P. Knaapen, M. J. W. Götte, and A. C. van Rossum, “The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis?” Journal of Cardiac Failure, vol. 15, no. 4, pp. 353–361, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. F. Locatelli, P. Aljama, B. Canaud et al., “Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with aranesp therapy (TREAT) study,” Nephrology Dialysis Transplantation, vol. 25, no. 9, pp. 2846–2850, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Kazory and E. A. Ross, “Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective,” Circulation, vol. 117, no. 7, pp. 975–983, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. S. G. Achinger and J. C. Ayus, “Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor?” Journal of the American Society of Nephrology, vol. 17, no. 12, supplement 3, pp. S255–S261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, “KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD),” Kidney International Supplements, vol. 76, pp. S1–S2, 2009. View at Publisher · View at Google Scholar
  92. S. D. Navaneethan, S. C. Palmer, M. Vecchio, J. C. Craig, G. J. Elder, and G. F. Strippoli, “Phosphate binders for preventing and treating bone disease in chronic kidney disease patients,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD006023, 2011. View at Google Scholar · View at Scopus
  93. J. Silver, M. Rodriguez, and E. Slatopolsky, “FGF23 and PTH—double agents at the heart of CKD,” Nephrology Dialysis Transplantation, vol. 27, no. 5, pp. 1715–1720, 2012. View at Publisher · View at Google Scholar
  94. C. Faul, A. P. Amaral, B. Oskouei et al., “FGF23 induces left ventricular hypertrophy,” Journal of Clinical Investigation, vol. 121, no. 11, pp. 4393–4408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. H. Fujii, J. I. Kim, T. Abe, M. Umezu, and M. Fukagawa, “Relationship between parathyroid hormone and cardiac abnormalities in chronic dialysis patients,” Internal Medicine, vol. 46, no. 18, pp. 1507–1512, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. R. E. Weishaar and R. U. Simpson, “Vitamin D3 and cardiovascular function in rats,” Journal of Clinical Investigation, vol. 79, no. 6, pp. 1706–1712, 1987. View at Google Scholar · View at Scopus
  97. M. Cozzolino and C. Ronco, “The impact of paricalcitol on left ventricular hypertrophy,” Contributions to Nephrology, vol. 171, pp. 161–165, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Wu, M. Garami, T. Cheng, and D. G. Gardner, “1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes,” Journal of Clinical Investigation, vol. 97, no. 7, pp. 1577–1588, 1996. View at Publisher · View at Google Scholar
  99. N. Bodyak, J. C. Ayus, S. Achinger et al., “Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 43, pp. 16810–16815, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Y. Wang, C. W. Lam, J. E. Sanderson et al., “Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study,” The American Journal of Clinical Nutrition, vol. 87, no. 6, pp. 1631–1638, 2008. View at Google Scholar · View at Scopus
  101. C. W. Park, Y. S. Oh, Y. S. Shin et al., “Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism,” The American Journal of Kidney Diseases, vol. 33, no. 1, pp. 73–81, 1999. View at Google Scholar · View at Scopus
  102. P. Ivarsen, J. V. Povlsen, and K. L. Christensen, “Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: a pilot study,” Scandinavian Journal of Urology, vol. 46, no. 5, pp. 381–388, 2012. View at Publisher · View at Google Scholar
  103. S. Bucharles, S. H. Barberato, A. E. M. Stinghen et al., “Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism,” Journal of Renal Nutrition, vol. 22, no. 2, pp. 284–291, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. R. Thadhani, E. Appelbaum, Y. Pritchett et al., “Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial,” The Journal of the American Medical Association, vol. 307, no. 7, pp. 674–684, 2012. View at Publisher · View at Google Scholar
  105. G. Ligtenberg, “Regulation of blood pressure in chronic renal failure: determinants of hypertension and dialysis-related hypotension,” Netherlands Journal of Medicine, vol. 55, no. 1, pp. 13–18, 1999. View at Publisher · View at Google Scholar · View at Scopus
  106. D. Bernardi, L. Bernini, G. Cini, S. Ghione, and I. Bonechi, “Asymmetric septal hypertrophy and sympathetic overactivity in normotensive hemodialyzed patients,” The American Heart Journal, vol. 109, no. 3, part 1, pp. 539–545, 1985. View at Google Scholar · View at Scopus
  107. C. Zoccali, F. Mallamaci, S. Parlongo et al., “Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease,” Circulation, vol. 105, no. 11, pp. 1354–1359, 2002. View at Publisher · View at Google Scholar · View at Scopus
  108. S. V. Badve, M. A. Roberts, C. M. Hawley et al., “Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis,” Journal of the American College of Cardiology, vol. 58, no. 11, pp. 1152–1161, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Ezekowitz, F. A. McAlister, K. H. Humphries et al., “The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease,” Journal of the American College of Cardiology, vol. 44, no. 8, pp. 1587–1592, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. M. G. Shlipak, W. S. Browner, H. Noguchi, B. Massie, C. D. Frances, and M. McClellan, “Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction,” The American Journal of Medicine, vol. 110, no. 6, pp. 425–433, 2001. View at Publisher · View at Google Scholar · View at Scopus
  111. K. C. Abbott, F. C. Trespalacios, L. Y. Agodoa, A. J. Taylor, and G. L. Bakris, “β-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality,” Archives of Internal Medicine, vol. 164, no. 22, pp. 2465–2471, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. J. K. Ghali, J. Wikstrand, D. J. van Veldhuisen et al., “The influence of renal function on clinical outcome and response to β-blockade in systolic heart failure: insights from metoprolol CR/XL randomized intervention trial in chronic HF (MERIT-HF),” Journal of Cardiac Failure, vol. 15, no. 4, pp. 310–318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. D. Castagno, P. S. Jhund, J. J. V. McMurray et al., “Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial,” European Journal of Heart Failure, vol. 12, no. 6, pp. 607–616, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Cohen-Solal, D. Kotecha, D. J. van Veldhuisen et al., “Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial,” European Journal of Heart Failure, vol. 11, no. 9, pp. 872–880, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. G. Cice, L. Ferrara, A. Di Benedetto et al., “Dilated cardiomyopathy in dialysis patients—beneficial effects of carvedilol: a double-blind, placebo-controlled trial,” Journal of the American College of Cardiology, vol. 37, no. 2, pp. 407–411, 2001. View at Publisher · View at Google Scholar · View at Scopus
  116. G. Cice, L. Ferrara, A. D'Andrea et al., “Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial,” Journal of the American College of Cardiology, vol. 41, no. 9, pp. 1438–1444, 2003. View at Publisher · View at Google Scholar · View at Scopus
  117. R. Ascenção, P. Fortuna, I. Reis, and A. V. Carneiro, “Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: a review. III. Angiotensin-converting enzyme inhibitors,” Revista Portuguesa de Cardiologia, vol. 27, no. 9, pp. 1169–1187, 2008. View at Google Scholar · View at Scopus
  118. N. Acquarone, C. Castello, G. Antonucci, S. Lione, and P. Bellotti, “Pharmacologic therapy in patients with chronic heart failure and chronic kidney disease: a complex issue,” Journal of Cardiovascular Medicine, vol. 10, no. 1, pp. 13–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. K. Amann, K. Tyralla, M. Gross et al., “Cardiomyocyte loss in experimental renal failure: prevention by ramipril,” Kidney International, vol. 63, no. 5, pp. 1708–1713, 2003. View at Publisher · View at Google Scholar · View at Scopus
  120. K. Amann, P. Gassmann, M. Buzello et al., “Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats,” Kidney International, vol. 58, no. 1, pp. 153–161, 2000. View at Publisher · View at Google Scholar · View at Scopus
  121. F. A. McAlister, J. Ezekowitz, M. Tonelli, and P. W. Armstrong, “Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study,” Circulation, vol. 109, no. 8, pp. 1004–1009, 2004. View at Publisher · View at Google Scholar · View at Scopus
  122. C. D. Frances, H. Noguchi, B. M. Massie, W. S. Browner, and M. McClellan, “Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function,” Archives of Internal Medicine, vol. 160, no. 17, pp. 2645–2650, 2000. View at Google Scholar · View at Scopus
  123. A. Ahmed, T. E. Love, X. Sui, and M. W. Rich, “Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis,” Journal of Cardiac Failure, vol. 12, no. 7, pp. 499–506, 2006. View at Publisher · View at Google Scholar · View at Scopus
  124. M. P. Tokmakova, H. Skali, S. Kenchaiah et al., “Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the survival and ventricular enlargement (SAVE) study,” Circulation, vol. 110, no. 24, pp. 3667–3673, 2004. View at Publisher · View at Google Scholar · View at Scopus
  125. C. B. Bowling, P. W. Sanders, R. M. Allman et al., “Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD treatment trial,” International Journal of Cardiology, vol. 167, no. 1, pp. 151–156, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. G. M. London, B. Pannier, A. P. Guerin, S. J. Marchais, M. E. Safar, and J. L. Cuche, “Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: comparative effects of ACE inhibition and calcium channel blockade,” Circulation, vol. 90, no. 6, pp. 2786–2796, 1994. View at Google Scholar · View at Scopus
  127. G. Cannella, E. Paoletti, R. Delfino, G. Peloso, D. Rolla, and S. Molinari, “Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects,” The American Journal of Kidney Diseases, vol. 30, no. 5, pp. 659–664, 1997. View at Google Scholar
  128. A. P. Guerin, J. Blacher, B. Pannier, S. J. Marchais, M. E. Safar, and G. M. London, “Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure,” Circulation, vol. 103, no. 7, pp. 987–992, 2001. View at Google Scholar · View at Scopus
  129. F. Zannad, M. Kessler, P. Lehert et al., “Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies,” Kidney International, vol. 70, no. 7, pp. 1318–1324, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. T. I. Chang, D. Shilane, S. M. Brunelli, A. K. Cheung, G. M. Chertow, and W. C. Winkelmayer, “Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis,” The American Heart Journal, vol. 162, no. 2, pp. 324–330, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. A. K. Berger, S. Duval, C. Manske et al., “Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease,” The American Heart Journal, vol. 153, no. 6, pp. 1064–1073, 2007. View at Publisher · View at Google Scholar · View at Scopus
  132. M. D. Flather, S. Yusuf, L. Køber et al., “Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients,” The Lancet, vol. 355, no. 9215, pp. 1575–1581, 2000. View at Google Scholar · View at Scopus
  133. G. L. Bakris and M. R. Weir, “Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?” Archives of Internal Medicine, vol. 160, no. 5, pp. 685–693, 2000. View at Google Scholar · View at Scopus
  134. N. A. Khan, I. Ma, C. R. Thompson et al., “Kidney function and mortality among patients with left ventricular systolic dysfunction,” Journal of the American Society of Nephrology, vol. 17, no. 1, pp. 244–253, 2006. View at Publisher · View at Google Scholar · View at Scopus
  135. A. H. Gradman and V. Papademetriou, “Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction,” The American Heart Journal, vol. 157, no. 6, supplement, pp. S17–S23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. S. de Denus, J. Tardif, M. White et al., “Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction. A retrospective analysis of the studies of left ventricular dysfunction (SOLVD) trials,” The American Heart Journal, vol. 152, no. 4, pp. 705–712, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. B. F. Palmer, “Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system,” The New England Journal of Medicine, vol. 351, no. 6, pp. 585–622, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. C. B. Granger, J. J. V. McMurray, S. Yusuf et al., “Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial,” The Lancet, vol. 362, no. 9386, pp. 772–776, 2003. View at Publisher · View at Google Scholar · View at Scopus
  139. J. N. Cohn and G. Tognoni, “A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure,” The New England Journal of Medicine, vol. 345, no. 23, pp. 1667–1675, 2001. View at Publisher · View at Google Scholar · View at Scopus
  140. M. Wong, L. Staszewsky, R. Latini et al., “Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study,” Journal of the American College of Cardiology, vol. 40, no. 5, pp. 970–975, 2002. View at Publisher · View at Google Scholar · View at Scopus
  141. M. A. Pfeffer, J. J. V. McMurray, E. J. Velazquez et al., “Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both,” The New England Journal of Medicine, vol. 349, no. 20, pp. 1893–1906, 2003. View at Publisher · View at Google Scholar · View at Scopus
  142. S. Yusuf, M. A. Pfeffer, K. Swedberg et al., “Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial,” The Lancet, vol. 362, no. 9386, pp. 777–781, 2003. View at Publisher · View at Google Scholar · View at Scopus
  143. B. M. Brenner, M. E. Cooper, D. de Zeeuw et al., “Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy,” The New England Journal of Medicine, vol. 345, no. 12, pp. 861–869, 2001. View at Publisher · View at Google Scholar · View at Scopus
  144. S. W. Tobe, C. M. Clase, P. Gao et al., “Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies,” Circulation, vol. 123, no. 10, pp. 1098–1107, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. A. Ahmed, G. C. Fonarow, Y. Zhang et al., “Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease,” The American Journal of Medicine, vol. 125, no. 4, pp. 399–410, 2012. View at Publisher · View at Google Scholar
  146. G. Cice, A. Di Benedetto, S. D'Isa et al., “Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: a double-blind, placebo-controlled trial,” Journal of the American College of Cardiology, vol. 56, no. 21, pp. 1701–1708, 2010. View at Publisher · View at Google Scholar · View at Scopus
  147. J. Staessen, P. Lijnen, R. Fagard, L. J. Verschueren, and A. Amery, “Rise in plasma concentration of aldosterone during long-term angiotensin II suppression,” Journal of Endocrinology, vol. 91, no. 3, pp. 457–465, 1981. View at Google Scholar · View at Scopus
  148. C. Borghi, S. Boschi, E. Ambrosioni, G. Melandri, A. Branzi, and B. Magnani, “Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ace inhibitors,” Journal of Clinical Pharmacology, vol. 33, no. 1, pp. 40–45, 1993. View at Google Scholar · View at Scopus
  149. K. T. Weber, “Aldosterone in congestive heart failure,” The New England Journal of Medicine, vol. 345, no. 23, pp. 1689–1697, 2001. View at Publisher · View at Google Scholar · View at Scopus
  150. M. Briet and E. L. Schiffrin, “Aldosterone: effects on the kidney and cardiovascular system,” Nature Reviews Nephrology, vol. 6, no. 5, pp. 261–273, 2010. View at Publisher · View at Google Scholar · View at Scopus
  151. B. Pitt, F. Zannad, W. J. Remme et al., “The effect of spironolactone on morbidity and mortality in patients with severe heart failure,” The New England Journal of Medicine, vol. 341, no. 10, pp. 709–717, 1999. View at Publisher · View at Google Scholar · View at Scopus
  152. B. Pitt, W. Remme, F. Zannad et al., “Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction,” The New England Journal of Medicine, vol. 348, no. 14, pp. 1309–1321, 2003. View at Publisher · View at Google Scholar · View at Scopus
  153. B. Pitt, H. White, J. Nicolau et al., “Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure,” Journal of the American College of Cardiology, vol. 46, no. 3, pp. 425–431, 2005. View at Publisher · View at Google Scholar · View at Scopus
  154. N. C. Edwards, R. P. Steeds, P. M. Stewart, C. J. Ferro, and J. N. Townend, “Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease. A randomized controlled trial,” Journal of the American College of Cardiology, vol. 54, no. 6, pp. 505–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  155. S. Taheri, M. Mortazavi, S. Shahidi et al., “Spironolactone in chronic hemodialysis patients improves cardiac function,” Saudi Journal of Kidney Diseases and Transplantation, vol. 20, no. 3, pp. 392–397, 2009. View at Google Scholar · View at Scopus
  156. S. Taheri, M. Mortazavi, A. Pourmoghadas, S. Seyrafian, Z. Alipour, and S. Karimi, “A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis,” Saudi Journal of Kidney Diseases and Transplantation, vol. 23, no. 3, pp. 507–512, 2012. View at Google Scholar
  157. D. Chua, A. Lo, and C. Lo, “Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?” Clinical Cardiology, vol. 33, no. 10, pp. 604–608, 2010. View at Publisher · View at Google Scholar · View at Scopus
  158. The Digitalis Investigation Group, “The effect of digoxin on mortality and morbidity in patients with heart failure,” The New England Journal of Medicine, vol. 336, no. 8, pp. 525–533, 1997. View at Google Scholar
  159. M. G. Shlipak, G. L. Smith, S. S. Rathore, B. M. Massie, and H. M. Krumholz, “Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2195–2203, 2004. View at Publisher · View at Google Scholar · View at Scopus
  160. A. Ahmed, M. W. Rich, T. E. Love et al., “Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial,” European Heart Journal, vol. 27, no. 2, pp. 178–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  161. D. R. Thiemann, “Digitalis and hemodialysis is a bad combination,” Journal of the American Society of Nephrology, vol. 21, no. 9, pp. 1418–1420, 2010. View at Publisher · View at Google Scholar · View at Scopus
  162. K. E. Chan, J. M. Lazarus, and R. M. Hakim, “Digoxin associates with mortality in ESRD,” Journal of the American Society of Nephrology, vol. 21, no. 9, pp. 1550–1559, 2010. View at Publisher · View at Google Scholar · View at Scopus
  163. G. B. Bleeker, J. J. Bax, P. Steendijk, M. J. Schalij, and E. E. van der Wall, “Left ventricular dyssynchrony in patients with heart failure: pathophysiology, diagnosis and treatment,” Nature Clinical Practice Cardiovascular Medicine, vol. 3, no. 4, pp. 213–219, 2006. View at Publisher · View at Google Scholar · View at Scopus
  164. M. Penicka, J. Bartunek, O. Lang et al., “Severe left ventricular dyssynchrony is associated with poor prognosis in patients with moderate systolic heart failure undergoing coronary artery bypass grafting,” Journal of the American College of Cardiology, vol. 50, no. 14, pp. 1315–1323, 2007. View at Publisher · View at Google Scholar · View at Scopus
  165. S. H. Shin, C. L. Hung, H. Uno et al., “Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both,” Circulation, vol. 121, no. 9, pp. 1096–1103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  166. F. A. McAlister, J. Ezekowitz, N. Hooton et al., “Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review,” The Journal of the American Medical Association, vol. 297, no. 22, pp. 2502–2514, 2007. View at Publisher · View at Google Scholar · View at Scopus
  167. L. A. Cannizzaro, J. P. Piccini, U. D. Patel, and A. F. Hernandez, “Device therapy in heart failure patients with chronic kidney disease,” Journal of the American College of Cardiology, vol. 58, no. 9, pp. 889–896, 2011. View at Publisher · View at Google Scholar · View at Scopus
  168. G. Boerrigter, L. C. Costello-Boerrigter, W. T. Abraham et al., “Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate,” Journal of Cardiac Failure, vol. 14, no. 7, pp. 539–546, 2008. View at Publisher · View at Google Scholar · View at Scopus
  169. A. Asif, L. H. Salman, G. G. Lopera, and R. G. Carrillo, “The dilemma of transvenous cardiac rhythm devices in hemodialysis patients: time to consider the epicardial approach,” Kidney International, vol. 79, no. 12, pp. 1267–1269, 2011. View at Publisher · View at Google Scholar · View at Scopus
  170. A. Ganda, S. D. Weiner, N. L. Chudasama et al., “Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fraction,” Clinical Nephrology, vol. 77, no. 5, pp. 366–375, 2012. View at Publisher · View at Google Scholar
  171. C. Libetta, V. Sepe, M. Zucchi et al., “Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines,” Nephrology Dialysis Transplantation, vol. 22, no. 7, pp. 2013–2019, 2007. View at Publisher · View at Google Scholar · View at Scopus
  172. C. W. McIntyre, “Haemodialysis-induced myocardial stunning in chronic kidney disease—a new aspect of cardiovascular disease,” Blood Purification, vol. 29, no. 2, pp. 105–110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  173. J. O. Burton, H. J. Jefferies, N. M. Selby, and C. W. McIntyre, “Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 12, pp. 1925–1931, 2009. View at Publisher · View at Google Scholar · View at Scopus
  174. N. M. Selby, S. H. Lambie, P. G. Camici, C. S. Baker, and C. W. McIntyre, “Occurrence of regional left ventricular dysfunction in patients undergoing standard and biofeedback dialysis,” The American Journal of Kidney Diseases, vol. 47, no. 5, pp. 830–841, 2006. View at Publisher · View at Google Scholar · View at Scopus
  175. N. M. Selby, J. O. Burton, L. J. Chesterton, and C. W. McIntyre, “Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate,” Clinical Journal of the American Society of Nephrology, vol. 1, no. 6, pp. 1216–1225, 2006. View at Publisher · View at Google Scholar · View at Scopus
  176. J. M. MacRae, S. Pandeya, D. P. Humen, N. Krivitski, and R. M. Lindsay, “Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms,” The American Journal of Kidney Diseases, vol. 43, no. 5, pp. e17–e22, 2004. View at Google Scholar · View at Scopus
  177. B. Charra, J. Bergstrom, and B. H. Scribner, “Blood pressure control in dialysis patients: importance of the lag phenomenon,” The American Journal of Kidney Diseases, vol. 32, no. 5, pp. 720–724, 1998. View at Google Scholar · View at Scopus
  178. B. F. Culleton, M. Walsh, S. W. Klarenbach et al., “Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial,” The Journal of the American Medical Association, vol. 298, no. 11, pp. 1291–1299, 2007. View at Publisher · View at Google Scholar · View at Scopus
  179. J. C. Ayus, M. R. Mizani, S. G. Achinger, R. Thadhani, A. S. Go, and S. Lee, “Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study,” Journal of the American Society of Nephrology, vol. 16, no. 9, pp. 2778–2788, 2005. View at Publisher · View at Google Scholar · View at Scopus
  180. C. T. Chan, P. J. Harvey, P. Picton, A. Pierratos, J. A. Miller, and J. S. Floras, “Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis,” Hypertension, vol. 42, no. 5, pp. 925–931, 2003. View at Publisher · View at Google Scholar · View at Scopus
  181. C. Chan, J. S. Floras, J. A. Miller, and A. Pierratos, “Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure,” Nephrology Dialysis Transplantation, vol. 17, no. 8, pp. 1518–1521, 2002. View at Google Scholar · View at Scopus
  182. C. T. Chan, T. Greene, G. M. Chertow et al., “Determinants of left ventricular mass in patients on hemodialysis: frequent hemodialysis network (FHN) trials,” Circulation: Cardiovascular Imaging, vol. 5, no. 2, pp. 251–261, 2012. View at Publisher · View at Google Scholar
  183. R. J. Hamburger, P. G. Christ, P. A. Morris, and F. C. Luft, “Hypertension in dialysis patients: does CAPD provide an advantage?” Advances in Peritoneal Dialysis, vol. 5, pp. 91–96, 1989. View at Google Scholar · View at Scopus
  184. N. Lameire, “Cardiovascular risk factors and blood pressure control in continuous ambulatory peritoneal dialysis,” Peritoneal Dialysis International, vol. 13, supplement 2, pp. S394–S395, 1993. View at Google Scholar · View at Scopus
  185. I. Dasgupta and R. Burden, “Blood pressure control before and after starting dialysis,” Nephron—Clinical Practice, vol. 99, no. 3, pp. c86–c91, 2005. View at Google Scholar · View at Scopus
  186. M. K. Menon, D. M. Naimark, J. M. Bargman, S. I. Vas, and D. G. Oreopoulos, “Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function,” Nephrology Dialysis Transplantation, vol. 16, no. 11, pp. 2207–2213, 2001. View at Google Scholar · View at Scopus
  187. K. Ateş, G. Nergizoǧlu, K. Keven et al., “Effect of fluid and sodium removal on mortality in peritoneal dialysis patients,” Kidney International, vol. 60, no. 2, pp. 767–776, 2001. View at Publisher · View at Google Scholar · View at Scopus
  188. G. Enia, F. Mallamaci, F. A. Benedetto et al., “Long-term CAPD patients are volume expanded and display more severe left venticular hypertrophy than haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 16, no. 7, pp. 1459–1464, 2001. View at Google Scholar · View at Scopus
  189. C. J. Konings, J. P. Kooman, M. Schonck et al., “Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study,” Nephrology Dialysis Transplantation, vol. 18, no. 4, pp. 797–803, 2003. View at Publisher · View at Google Scholar · View at Scopus
  190. P. J. Margetts and D. N. Churchill, “Acquired ultrafiltration dysfunction in peritoneal dialysis patients,” Journal of the American Society of Nephrology, vol. 13, no. 11, pp. 2787–2794, 2002. View at Google Scholar · View at Scopus
  191. G. Aşci, M. Özkahya, S. Duman, H. Toz, S. Erten, and E. Ok, “Volume control associated with better cardiac function in long-term peritoneal dialysis patients,” Peritoneal Dialysis International, vol. 26, no. 1, pp. 85–88, 2006. View at Google Scholar · View at Scopus
  192. C. J. Konings, J. P. Kooman, M. Schonck et al., “Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study,” Kidney International, vol. 63, no. 4, pp. 1556–1563, 2003. View at Publisher · View at Google Scholar · View at Scopus
  193. A. G. Stack, D. A. Molony, N. S. Rahman, A. Dosekun, and B. Murthy, “Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States,” Kidney International, vol. 64, no. 3, pp. 1071–1079, 2003. View at Publisher · View at Google Scholar · View at Scopus
  194. E. F. Vonesh, J. J. Snyder, R. N. Foley, and A. J. Collins, “The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis,” Kidney International, vol. 66, no. 6, pp. 2389–2401, 2004. View at Google Scholar · View at Scopus
  195. J. J. V. McMurray, B. Pitt, R. Latini et al., “Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure,” Circulation: Heart Failure, vol. 1, no. 1, pp. 17–24, 2008. View at Google Scholar · View at Scopus
  196. P. S. Sever, A. H. Gradman, and M. Azizi, “Managing cardiovascular and renal risk: the potential of direct renin inhibition,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 10, no. 2, pp. 65–76, 2009. View at Publisher · View at Google Scholar · View at Scopus
  197. B. Pitt, G. Filippatos, M. Gheorghiade et al., “Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease,” European Journal of Heart Failure, vol. 14, no. 6, pp. 668–675, 2012. View at Publisher · View at Google Scholar
  198. E. S. Chung, M. Packer, K. H. Lo, A. A. Fasanmade, and J. T. Willerson, “Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial,” Circulation, vol. 107, no. 25, pp. 3133–3140, 2003. View at Publisher · View at Google Scholar · View at Scopus
  199. D. L. Mann, J. J. V. McMurray, M. Packer et al., “Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL),” Circulation, vol. 109, no. 13, pp. 1594–1602, 2004. View at Publisher · View at Google Scholar · View at Scopus
  200. N. F. Kelland and D. J. Webb, “Clinical trials of endothelin antagonists in heart failure: a question of dose?” Experimental Biology and Medicine, vol. 231, no. 6, pp. 696–699, 2006. View at Google Scholar · View at Scopus
  201. M. Packer, R. M. Califf, M. A. Konstam et al., “Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE),” Circulation, vol. 106, no. 8, pp. 920–926, 2002. View at Publisher · View at Google Scholar · View at Scopus
  202. T. Reilly and M. R. Schork, “Vasopressin antagonists: pharmacotherapy for the treatment of heart failure,” Annals of Pharmacotherapy, vol. 44, no. 4, pp. 680–687, 2010. View at Publisher · View at Google Scholar · View at Scopus
  203. Y. Sata and H. Krum, “The future of pharmacological therapy for heart failure,” Circulation Journal, vol. 74, no. 5, pp. 809–817, 2010. View at Publisher · View at Google Scholar · View at Scopus